US-based Teligent saw its revenues drop to $10.4m in the second quarter of 2021, compared to $13.6m reported in the prior year period, with president and CEO Tim Sawyer citing a combination of factors for the underwhelming quarter including “remediation-related activities, the ongoing effects of the COVID-19 pandemic and modest generic pricing erosion seen within the topicals segment.”
However, the company indicated that it was exploring options to strengthen its injectables segment. “Looking ahead,” Sawyer said, “we are...




